BIOMAT Database Logo BIOMAT Database Logo

Daily cost of ophthalmic solutions used to treat allergic conjunctivitis in Japan. 2004

Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Department of Pharmaceutical Services, Hiroshima University Hospital, Hiroshima, Japan. ike@hiroshima-u.ac.jp

OBJECTIVE To estimate the daily cost of various ophthalmic solutions used in Japan for treating allergic conjunctivitis, including nine anti-allergic drugs and six anti-inflammatory drugs. METHODS The drops contained in one bottle of each solution were counted. The cost per drop was calculated by dividing the government-controlled standard prices by the total number of drops in one bottle, and the daily cost of therapy was calculated by multiplying the cost per drop by the number of drops to be given per day. RESULTS The total number of drops of the anti-allergic drugs in a bottle ranged from 108 to 169 and that of the anti-inflammatory drugs from 100 to 145. The information in the package insert for these solutions recommends application 2-4 times daily. The price of the antiallergic drugs studied ranged from $6.35 to $8.38 and that of the anti-inflammatory drugs studied from $2.02 to $5.20. The daily cost of the anti-allergic drugs studied varied considerably, from $0.26 to $0.57; for the anti-inflammatory drugs the range was from $0.12 to $0.20. Variations in the total number of drops per bottle and in the recommended dosage affect the daily cost of ophthalmic solutions. CONCLUSIONS At current prices, the volume of a drop and the dosage had a greater effect on the daily cost than the price of a bottle. Daily cost data may be helpful in selecting ophthalmic products for treating allergic conjunctivitis in settings where the prices of a given drug are relatively uniform.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D009883 Ophthalmic Solutions Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. Eye Drop,Eyedrop,Eyedrops,Ophthalmic Solution,Eye Drops,Drop, Eye,Drops, Eye,Solution, Ophthalmic,Solutions, Ophthalmic
D003233 Conjunctivitis, Allergic Conjunctivitis due to hypersensitivity to various allergens. Allergic Conjunctivitis,Conjunctivitis, Atopic,Conjunctivitis, Giant Papillary,Conjunctivitis, Vernal,Keratoconjunctivitis, Vernal,Allergic Conjunctivitides,Atopic Conjunctivitides,Atopic Conjunctivitis,Conjunctivitides, Allergic,Conjunctivitides, Atopic,Conjunctivitides, Giant Papillary,Conjunctivitides, Vernal,Giant Papillary Conjunctivitides,Giant Papillary Conjunctivitis,Keratoconjunctivitides, Vernal,Papillary Conjunctivitides, Giant,Papillary Conjunctivitis, Giant,Vernal Conjunctivitides,Vernal Conjunctivitis,Vernal Keratoconjunctivitides,Vernal Keratoconjunctivitis
D003365 Costs and Cost Analysis Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs. Affordability,Analysis, Cost,Cost,Cost Analysis,Cost Comparison,Cost Measures,Cost-Minimization Analysis,Costs and Cost Analyses,Costs, Cost Analysis,Pricing,Affordabilities,Analyses, Cost,Analyses, Cost-Minimization,Analysis, Cost-Minimization,Comparison, Cost,Comparisons, Cost,Cost Analyses,Cost Comparisons,Cost Measure,Cost Minimization Analysis,Cost, Cost Analysis,Cost-Minimization Analyses,Costs,Measure, Cost,Measures, Cost
D004358 Drug Therapy The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER. Chemotherapy,Pharmacotherapy,Therapy, Drug,Chemotherapies,Drug Therapies,Pharmacotherapies,Therapies, Drug
D005252 Fees, Pharmaceutical Amounts charged to the patient or third-party payer for medication. It includes the pharmacist's professional fee and cost of ingredients, containers, etc. Fee, Pharmacy,Fees, Pharmaceutic,Pharmaceutical Fees,Pharmacy Fee,Fee, Pharmaceutic,Fee, Pharmaceutical,Fees, Pharmacy,Pharmaceutic Fee,Pharmaceutic Fees,Pharmaceutical Fee,Pharmacy Fees
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D016527 Drug Costs The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES). Cost, Drug,Costs, Drug,Drug Cost
D017048 Health Care Costs The actual costs of providing services related to the delivery of health care, including the costs of procedures, therapies, and medications. It is differentiated from HEALTH EXPENDITURES, which refers to the amount of money paid for the services, and from fees, which refers to the amount charged, regardless of cost. Medical Care Costs,Treatment Costs,Costs, Medical Care,Health Costs,Healthcare Costs,Cost, Health,Cost, Health Care,Cost, Healthcare,Cost, Medical Care,Cost, Treatment,Costs, Health,Costs, Health Care,Costs, Healthcare,Costs, Treatment,Health Care Cost,Health Cost,Healthcare Cost,Medical Care Cost,Treatment Cost

Related Publications

Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Daily cost of ophthalmic solutions for treating glaucoma in Japan.
January 2001, Japanese journal of ophthalmology,
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
July 2010, American journal of ophthalmology,
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
[TREATMENT WITH OPHTHALMIC SOLUTIONS AND SELFCARE FOR ALLERGIC CONJUNCTIVITIS].
January 2021, Arerugi = [Allergy],
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Nedocromil sodium ophthalmic solution 2% twice daily in patients with allergic conjunctivitis.
January 2002, Advances in therapy,
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Ophthalmic levocabastine for allergic conjunctivitis.
April 1994, The Medical letter on drugs and therapeutics,
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Once-daily olopatadine ophthalmic solution 0.2% in the treatment of allergic conjunctivitis and rhinoconjunctivitis.
June 2007, Expert review of pharmacoeconomics & outcomes research,
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Twice-daily and once-daily nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis.
January 2002, Advances in therapy,
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Comparative study of ophthalmic decongestants in allergic conjunctivitis.
May 1958, Journal of the American Medical Association,
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
Supplementation of fexofenadine therapy with nedocromil sodium 2% ophthalmic solution to treat ocular symptoms of seasonal allergic conjunctivitis.
June 2003, Clinical & experimental ophthalmology,
Hiroaki Ikeda, and Hidetoshi Tsukamoto, and Eiji Sato, and Hiromu K Mishima, and Kenji Kihira
A review of plant species used to treat conjunctivitis.
February 2002, Phytotherapy research : PTR,
Copied contents to your clipboard!